507475-17-4 | 5-(4-FLUOROPHENYL)-2-UREIDOTHIOPHENE-3-CARBOXAMIDE

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$29.00	$20.00
5mg	98%	in stock	$63.00	$44.00
10mg	98%	in stock	$78.00	$54.00
100mg	98%	in stock	$299.00	$209.00
250mg	98%	in stock	$473.00	$331.00
1g	98%	in stock	$1,311.00	$918.00

Description

• Catalog Number: AD21392
• Chemical Name: 5-(4-FLUOROPHENYL)-2-UREIDOTHIOPHENE-3-CARBOXAMIDE
• CAS Number: 507475-17-4
• Molecular Formula: C12H10FN3O2S
• Molecular Weight: 279.2901
• MDL Number: MFCD09037541
• SMILES: NC(=O)Nc1sc(cc1C(=O)N)c1ccc(cc1)F

Computed Properties

• Complexity: 361
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 3
• XLogP3: 1.7

Literature

• IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.

  The Journal of biological chemistry 20171110

• MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β.

  The Journal of biological chemistry 20170317

• Small-molecule inhibitors of IκB kinase (IKK) and IKK-related kinases.

  Pharmaceutical patent analyst 20130701

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20120801

• NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.

  Biochemical and biophysical research communications 20120713

• Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.

  Journal of medicinal chemistry 20120524

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.

  Journal of natural products 20110826

• Identification of new inhibitors of protein kinase R guided by statistical modeling.

  Bioorganic & medicinal chemistry letters 20110701

• IKK-2 inhibitor TPCA-1 represses nasal epithelial inflammation in vitro.

  Rhinology 20110601

• Identification of angular naphthopyrones from the Philippine echinoderm Comanthus species as inhibitors of the NF-κB signaling pathway.

  European journal of pharmacology 20110425

• 3,5-Disubstituted-indole-7-carboxamides: the discovery of a novel series of potent, selective inhibitors of IKK-β.

  Bioorganic & medicinal chemistry letters 20110415

• Pancreatic β-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis.

  PloS one 20110101

• Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion.

  PloS one 20110101

• Investigation of nuclear factor-κB inhibitors and interleukin-10 as regulators of inflammatory signalling in human adipocytes.

  Clinical and experimental immunology 20101201

• Inhibitor of kappaB kinase beta regulates redox homeostasis by controlling the constitutive levels of glutathione.

  Molecular pharmacology 20100501

• Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1.

  British journal of pharmacology 20090601

• IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.

  Bioorganic & medicinal chemistry 20090401

• Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

  Journal of medicinal chemistry 20081225

• Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture.

  Investigative ophthalmology & visual science 20081101

• The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells.

  Journal of immunology (Baltimore, Md. : 1950) 20071101

• BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.

  Blood 20070615

• Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model.

  The European respiratory journal 20061201

• IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic.

  Molecular pharmacology 20060601

• Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes.

  American journal of physiology. Regulatory, integrative and comparative physiology 20060301

• Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma.

  American journal of respiratory and critical care medicine 20051015

• Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation.

  The Journal of pharmacology and experimental therapeutics 20050101